Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Germ Cell Tumors
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(36)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
ifosfamide
Sensitive: A1 - Approval
ifosfamide
Sensitive
:
A1
ifosfamide
Sensitive: A1 - Approval
ifosfamide
Sensitive
:
A1
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
TMB-H
Germ Cell Tumors
TMB-H
Germ Cell Tumors
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
paclitaxel + ifosfamide
Sensitive: A2 - Guideline
paclitaxel + ifosfamide
Sensitive
:
A2
paclitaxel + ifosfamide
Sensitive: A2 - Guideline
paclitaxel + ifosfamide
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
gemcitabine + paclitaxel
Sensitive: A2 - Guideline
gemcitabine + paclitaxel
Sensitive
:
A2
gemcitabine + paclitaxel
Sensitive: A2 - Guideline
gemcitabine + paclitaxel
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
carboplatin + docetaxel
Sensitive: A2 - Guideline
carboplatin + docetaxel
Sensitive
:
A2
carboplatin + docetaxel
Sensitive: A2 - Guideline
carboplatin + docetaxel
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
gemcitabine + paclitaxel + oxaliplatin
Sensitive: A2 - Guideline
gemcitabine + paclitaxel + oxaliplatin
Sensitive
:
A2
gemcitabine + paclitaxel + oxaliplatin
Sensitive: A2 - Guideline
gemcitabine + paclitaxel + oxaliplatin
Sensitive
:
A2
MSI-H/dMMR
Germ Cell Tumors
MSI-H/dMMR
Germ Cell Tumors
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
BRCA1 mutation
Germ Cell Tumors
BRCA1 mutation
Germ Cell Tumors
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
XPA expression
Germ Cell Tumors
XPA expression
Germ Cell Tumors
cisplatin
Resistant: C3 – Early Trials
cisplatin
Resistant
:
C3
cisplatin
Resistant: C3 – Early Trials
cisplatin
Resistant
:
C3
MTOR mutation
Germ Cell Tumors
MTOR mutation
Germ Cell Tumors
everolimus
Sensitive: C3 – Early Trials
everolimus
Sensitive
:
C3
everolimus
Sensitive: C3 – Early Trials
everolimus
Sensitive
:
C3
KRAS amplification
Germ Cell Tumors
KRAS amplification
Germ Cell Tumors
MEK inhibitor
Sensitive: C3 – Early Trials
MEK inhibitor
Sensitive
:
C3
MEK inhibitor
Sensitive: C3 – Early Trials
MEK inhibitor
Sensitive
:
C3
Chr t(22)
Germ Cell Tumors
Chr t(22)
Germ Cell Tumors
cisplatin + ifosfamide + etoposide oral + mesna
Sensitive: C4 – Case Studies
cisplatin + ifosfamide + etoposide oral + mesna
Sensitive
:
C4
cisplatin + ifosfamide + etoposide oral + mesna
Sensitive: C4 – Case Studies
cisplatin + ifosfamide + etoposide oral + mesna
Sensitive
:
C4
EGFR L858R
Germ Cell Tumors
EGFR L858R
Germ Cell Tumors
icotinib
Sensitive: C4 – Case Studies
icotinib
Sensitive
:
C4
icotinib
Sensitive: C4 – Case Studies
icotinib
Sensitive
:
C4
BAX underexpression
Germ Cell Tumors
BAX underexpression
Germ Cell Tumors
cisplatin
Resistant: C4 – Case Studies
cisplatin
Resistant
:
C4
cisplatin
Resistant: C4 – Case Studies
cisplatin
Resistant
:
C4
TP53 mutation
Germ Cell Tumors
TP53 mutation
Germ Cell Tumors
cisplatin
Resistant: C4 – Case Studies
cisplatin
Resistant
:
C4
cisplatin
Resistant: C4 – Case Studies
cisplatin
Resistant
:
C4
EGFR L858R
Germ Cell Tumors
EGFR L858R
Germ Cell Tumors
icotinib
Sensitive: C4 – Case Studies
icotinib
Sensitive
:
C4
icotinib
Sensitive: C4 – Case Studies
icotinib
Sensitive
:
C4
MSH6 mutation
Germ Cell Tumors
MSH6 mutation
Germ Cell Tumors
camrelizumab
Sensitive: C4 – Case Studies
camrelizumab
Sensitive
:
C4
camrelizumab
Sensitive: C4 – Case Studies
camrelizumab
Sensitive
:
C4
BRCA2 mutation
Germ Cell Tumors
BRCA2 mutation
Germ Cell Tumors
camrelizumab
Sensitive: C4 – Case Studies
camrelizumab
Sensitive
:
C4
camrelizumab
Sensitive: C4 – Case Studies
camrelizumab
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login